Caplin Point Laboratories Limited (NSE:CAPLIPOINT)
2,008.40
-15.40 (-0.76%)
May 15, 2026, 3:29 PM IST
Caplin Point Laboratories Revenue
In the fiscal year ending March 31, 2026, Caplin Point Laboratories had annual revenue of 23.03B INR with 18.72% growth. Caplin Point Laboratories had revenue of 6.29B in the quarter ending March 31, 2026, with 24.57% growth.
Revenue
23.03B
Revenue Growth
+18.72%
P/S Ratio
6.60
Revenue / Employee
5.81M
Employees
3,966
Market Cap
151.94B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 23.03B | 3.63B | 18.72% |
| Mar 31, 2025 | 19.40B | 2.43B | 14.35% |
| Mar 31, 2024 | 16.96B | 2.28B | 15.51% |
| Mar 31, 2023 | 14.68B | 1.97B | 15.53% |
| Mar 31, 2022 | 12.71B | 2.09B | 19.64% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Piramal Pharma | 88.69B |
| Alembic Pharmaceuticals | 73.99B |
| Gland Pharma | 67.47B |
| Strides Pharma Science | 47.26B |
| NATCO Pharma | 45.63B |
| Akums Drugs and Pharmaceuticals | 44.88B |
| Wockhardt | 34.84B |
| Eris Lifesciences | 30.65B |
Caplin Point Laboratories News
- 3 days ago - Caplin Point Laboratories Transcript: Q4 25/26 - Transcripts
- 12 days ago - Caplin Point subsidiary receives USFDA approval for Calcium Gluconate Injection; targets $71 million US market - Business Upturn
- 2 months ago - Caplin Point receives USFDA approval for potassium phosphates injection - Business Upturn
- 2 months ago - Caplin Point Laboratories arm receives USFDA approval for potassium phosphates injection - Business Upturn
- 2 months ago - Caplin Point subsidiary secures USFDA final approval for Desmopressin Acetate Injection ANDA - Business Upturn
- 2 months ago - Caplin Point subsidiary secures USFDA approval for Sodium Phosphates Injection - Business Upturn
- 3 months ago - Caplin Point Laboratories Ltd (BOM:524742) Q3 2026 Earnings Call Highlights: Navigating Growth ... - GuruFocus
- 3 months ago - Q3 2026 Caplin Point Laboratories Ltd Earnings Call Transcript - GuruFocus